ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0156

Advanced Mouse Models of Diabetic Kidney Disease (DKD) in Type 2 Diabetes

Session Information

Category: Cardiovascular-Kidney-Metabolic Health

  • 601 Cardiovascular-Kidney-Metabolic Health: Basic

Authors

  • Luo, Kaiming, WuXi AppTec, Shanghai, China
  • Li, Dan, WuXi AppTec, Shanghai, China
  • Qi, Hao, WuXi AppTec, Shanghai, China
Background

Globally, diabetic kidney disease (DKD) is a major long-term complication of type 1 and type 2 diabetes, affecting 20%–40% of diabetic patients, among whom 40%–50% eventually progress to end-stage renal disease. Research on mid-to-late-stage DKD is hindered by an extremely long phenotypic onset period, typically over 40 weeks. There is therefore an urgent need to develop appropriate animal models that recapitulate the mid-to-late stages of diabetes within a shorter timeframe (<20 weeks). To support the development of novel therapeutic strategies for halting DKD progression, we established two mouse models mimicking the mid-to-late stages of type 2 diabetes.

Methods

Model 1#: Male db/db mice (8–10 weeks old) were injected with Renin-encoding AAV two weeks prior to unilateral nephrectomy (UNx). Renin adeno-associated virus was delivered to induce hypertension and thereby accelerate DKD progression in db/db mice.

Model 2#: Global eNOS knockout was generated on a db/db diabetic background. eNOS deficiency in db/db mice exacerbates endothelial dysfunction and glomerular hyperfiltration, further accelerating the onset and progression of diabetic renal injury.

In-life and terminal evaluations included blood and urinary biochemistry, blood glucose, blood pressure, glomerular filtration rate (GFR), and pathological examinations via H&E, PAS and IHC staining.

Results

In Model 1#, mice exhibited elevated urinary ACR and KIM-1 levels, as well as increased serum creatinine and BUN. Blood pressure was elevated as expected. The Renin-AAV UNx db/db model showed markedly increased histological scores, accompanied by renal interstitial inflammatory infiltration, tubular damage, interstitial fibrosis and glomerulosclerosis, which recapitulate the key pathological features of late-stage DKD.

Consistently, Model 2# (BKS-db-eNOS KO mice) displayed increased urinary ACR and blood pressure. GFR was significantly decreased in BKS-db-eNOS KO mice, indicating impaired renal function. H&E and PAS staining revealed aggravated tubular injury, tubular atrophy and dilation, interstitial fibrosis, and a higher glomerulosclerotic index.

Conclusion

Either the Renin-AAV UNx db/db model or the BKS-db-eNOS KO model is well-suited for investigating mid-to-late diabetic nephropathy, and provides reliable platforms for preclinical studies on late-stage DKD.